全文获取类型
收费全文 | 27059篇 |
免费 | 1803篇 |
国内免费 | 126篇 |
专业分类
耳鼻咽喉 | 217篇 |
儿科学 | 847篇 |
妇产科学 | 620篇 |
基础医学 | 3548篇 |
口腔科学 | 446篇 |
临床医学 | 2395篇 |
内科学 | 6475篇 |
皮肤病学 | 640篇 |
神经病学 | 2755篇 |
特种医学 | 760篇 |
外科学 | 2833篇 |
综合类 | 263篇 |
一般理论 | 12篇 |
预防医学 | 2682篇 |
眼科学 | 495篇 |
药学 | 2029篇 |
中国医学 | 96篇 |
肿瘤学 | 1875篇 |
出版年
2024年 | 33篇 |
2023年 | 270篇 |
2022年 | 580篇 |
2021年 | 1089篇 |
2020年 | 535篇 |
2019年 | 857篇 |
2018年 | 1066篇 |
2017年 | 699篇 |
2016年 | 732篇 |
2015年 | 852篇 |
2014年 | 1066篇 |
2013年 | 1449篇 |
2012年 | 2056篇 |
2011年 | 2177篇 |
2010年 | 1281篇 |
2009年 | 1005篇 |
2008年 | 1709篇 |
2007年 | 1776篇 |
2006年 | 1595篇 |
2005年 | 1540篇 |
2004年 | 1381篇 |
2003年 | 1301篇 |
2002年 | 1200篇 |
2001年 | 346篇 |
2000年 | 397篇 |
1999年 | 327篇 |
1998年 | 189篇 |
1997年 | 140篇 |
1996年 | 95篇 |
1995年 | 86篇 |
1994年 | 95篇 |
1993年 | 67篇 |
1992年 | 119篇 |
1991年 | 95篇 |
1990年 | 79篇 |
1989年 | 74篇 |
1988年 | 54篇 |
1987年 | 48篇 |
1986年 | 55篇 |
1985年 | 43篇 |
1984年 | 26篇 |
1983年 | 26篇 |
1982年 | 29篇 |
1981年 | 33篇 |
1979年 | 31篇 |
1978年 | 31篇 |
1977年 | 33篇 |
1976年 | 30篇 |
1974年 | 26篇 |
1972年 | 22篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.
ContextZD4054 is a specific endothelin A (ETA) receptor antagonist being investigated for the treatment of hormone-resistant prostate cancer (HRPC). ZD4054 binds specifically to the ETA receptor, with no detectable activity at the ETB receptor. In preclinical studies, ZD4054 inhibited endothelin (ET-1)-mediated changes in cellular invasiveness in vitro, and inhibited angiogenesis and growth of tumour xenografts in vivo. Consistent with its specific binding profile, ZD4054 inhibited ETA-receptor-mediated antiapoptotic events while allowing ETB-receptor-mediated proapoptotic signalling.Evidence acquisitionThe preclinical and clinical activity of ZD4054 is reviewed.Evidence synthesisIn the clinical setting, stable levels of circulating ET-1 following single ZD4054 doses up to 240 mg demonstrated the absence of ZD4054 activity at the ETB receptor. ZD4054 is cleared principally via the urine, with a terminal elimination half-life of approximately 8–12 hours and with little accumulation after once-daily oral dosing.In a Phase 2 trial, patients with metastatic HRPC who were pain free or mildly symptomatic for pain were randomized to once-daily oral tablets of ZD4054 10 mg (n = 107), or 15 mg (n = 98), or matched placebo (n = 107). ZD4054 was generally well tolerated in this population, with an adverse effect profile consistent with its known pharmacological activity. The most common adverse effects were headache, peripheral oedema and nasal congestion. At the primary analysis there was no statistically significant difference in time to progression between the ZD4054-treated groups and placebo (hazard ratio [HR]: ZD4054 10 mg, 0.88 [80% CI 0.71, 1.09]; ZD4054 15 mg, 0.83 [0.66, 1.03]). However, a promising signal for prolonged overall survival was observed, which was sustained at a subsequent analysis (HR versus placebo: ZD4054 10 mg, 0.55 [80% CI 0.41, 0.73]; ZD4054 15 mg, 0.65 [0.49, 0.86]).ConclusionsThese results support the strategy of targeting the ETA receptor in prostate cancer, and mandate further investigation of ZD4054 in Phase 3 clinical trials. 相似文献
42.
43.
44.
David Jiménez Castro Gema Díaz David Martí Carlos Escobar Javier Ortega Sergio García-Rull Joaquin Picher Antonio Sueiro 《Blood coagulation & fibrinolysis》2007,18(2):173-177
This study aimed to determine whether a weight-adjusted dose of subcutaneous enoxaparin is as effective and safe as oral acenocoumarol for the secondary prophylaxis of pulmonary embolism. Three hundred and eighty consecutive noncancer outpatients hospitalized with an episode of symptomatic pulmonary embolism selected treatment with acenocoumarol or enoxaparin at a dose of 1 mg/kg once daily after being informed of the type of administration and expected frequency of laboratory monitoring for both medicinal products. Endpoints were symptomatic recurrent thromboembolic events evaluated by standard objective testing, and a composite endpoint of recurrent venous thromboembolism, major bleeding, and death from any cause. One hundred and ninety-nine patients (52%) chose acenocoumarol therapy and 181 chose enoxaparin monotherapy. Four patients in the enoxaparin group (2.2%) and six patients in the acenocoumarol group (3%) had an objective thromboembolic recurrence (hazard ratio, 1.35; 95% confidence interval, 0.38-4.79; P = 0.64). Nine patients in the enoxaparin group (5.0%) had a hemorrhagic complication compared with 11 in the acenocoumarol group (5.5%) (P = 0.81). The hospital length of stay was shorter with enoxaparin compared with acenocoumarol (11 versus 16 days, P = 0.0001). Enoxaparin is as effective and safe as acenocoumarol in the secondary prevention of recurrent thromboembolic disease and is associated with shorter hospitalization. 相似文献
45.
46.
47.
Heather S. Jim Michael A. Andrykowski Pamela N. Munster Paul B. Jacobsen 《Annals of behavioral medicine》2007,34(2):200-208
Background: Studies suggest that the period following completion of treatment can be distressing for cancer patients. One potentially
important predictor of distress is physical symptoms/side effects during treatment.Purpose: A longitudinal, observational design was used to examine whether the number of physical symptoms/side effects experienced
during treatment was a correlate of cancer-related distress and general distress 4 months after treatment completion, as measured
by the Impact of Events Scale and the Mental Health subscale of the Short Form-36, respectively.Methods: Participants were 151 women who had completed chemotherapy and/or radiotherapy for ductal carcinoma in situ or stage 1 or
2 breast cancer. Hierarchical multiple regression was conducted with relevant sociodemographic, clinical, and psychiatric
variables entered as controls.Results: Greater physical symptoms/side effects predicted greater total cancer-related distress, intrusive thoughts, and general distress.
Physical symptoms/side effects did not significantly predict avoidance. Follow-up analyses indicated that the relationship
between physical symptoms/side effects and general distress was mediated by both total cancer-related distress and intrusive
thoughts.Conclusions: These results suggest that patients who experience greater physical symptoms/side effects during treatment are at greater
risk for later cancer-related distress and, in turn, general distress. Future research should evaluate whether early intervention
with these patients is effective in preventing or reducing distress in the posttreatment period.
This work was supported by a grant from the National Cancer Institute (5R01 CA082822). 相似文献
48.
Gy?rgy Lang Attila Cseke? Georgios Stamatis Ludwig Lampl Leif Hagman Gabriel Mihai Marta Michael Rolf Mueller Walter Klepetko 《European journal of cardio-thoracic surgery》2004,25(2):160-166
OBJECTIVES: Persisting air leakage after pulmonary resection remains a significant problem. The aim of the study was to evaluate the incidence of air leakage after standard lobectomy and test the efficacy and safety of TachoComb (TC). METHODS: A total of 189 patients undergoing lobectomy were enrolled in a multi-centre, open, randomised, and prospective study to test the efficacy and safety of TachoComb (TC) for air leakage treatment. Air leakage was assessed by water submersion test, and scored as grades 0 if no, 1 if countable, 2 if a stream of and 3 if coalescent bubbles have been observed. Any sites with grade 3 air leakage received further stapling or limited suturing until grade 0, 1 or 2 was obtained. Treatment of air leakage was done with TC or suturing according to randomisation. Air leakage was assessed by further submersion tests. Postoperative air leakage was assessed using the Pleur-Evac system. RESULTS: Overall incidence of air leakage 48+/-6 h after surgery was 34% for TC and 37% for standard treatment (P=0.76). The reduction of intra-operative air leak intensity in the subgroup with grades 1-2 was significantly higher for the TC group (P=0.015). Postoperative air leakage intensity in the subgroup with air leakage grades 1-2 was lower for TC than standard treatment (P=0.047). The mean duration of postoperative air leakage in the subgroup with grades 1-2 was shorter for the TC group than for standard treatment, i.e. 1.9+/-1.4 vs. 2.7+/-2.2 days (P=0.015). CONCLUSIONS: TC could be proven as well-tolerated and safe. In the subgroup of patients with established air leakage, TC showed superior potential in reduction of intra-operative air leakage as well as in reduction of intensity and duration of postoperative air leakage. 相似文献
49.
50.
SK&F 86466, 6-chloro-3-methyl-2,3,4,5-tetrahydro-1-H-3-benzazepine, is a potent and selective antagonist of the α2-adrenoceptor in vitro. This compound produced a small pressor response accompanied by a marked bradycardia when administered i.v. to the pithed normotensive rat. The pressor response was not affected by reserpine treatment, pretreatment with α- or β-adrenoceptor antagonists, atropine, or hexamethonium. The bradycardia was markedly reduced by bilateral vagotomy and pretreatment with atropine and attenuated by hexamethonium. The negative chronotropic action of SK&F 86466 was abolished by a combination of vagotomy and atropine. Mediation of the bradycardia by a baroreceptor reflex was ruled out by the observations that a lack of change in heart rate was associated with the vasopressor response to phenylephrine in the pithed rat pretreated with propranolol. It is concluded that the negative chronotropic action of SK&F 86466 in the pithed rat is mediated indirectly by activation of the cholinergic innervation of the heart. 相似文献